Lexaria Bioscience Corp.
LEXX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001348362
No open-market purchases or sales by Lexaria Bioscience Corp. insiders were filed in the last 90 days; 31 institutions reported holding it in 13F filings for Q2 2026, worth $920.0K in total; no superinvestor holds it.
13F holders, Q3 2022
Institutional positions in Lexaria Bioscience Corp. as of Sep 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 16
- 0 vs. Q2 2022
- Shares held
- 687.7K
- +125.9K (+22.4%) vs. Q2 2022
- Total value
- $1.68M
- +$10.0K (+0.6%) vs. Q2 2022
- New holders
- 3
- 4 more added
- Sold out
- 3
- 5 more reduced
Compare with Q2 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting LEXX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 31 | $920.0K |
| Q1 2026 | 28 | $1.17M |
| Q4 2025 | 21 | $1.05M |
| Q3 2025 | 25 | $1.63M |
| Q2 2025 | 21 | $2.00M |
| Q1 2025 | 22 | $2.12M |
| Q4 2024 | 25 | $3.03M |
| Q3 2024 | 27 | $3.25M |
| Q2 2024 | 28 | $5.72M |
| Q1 2024 | 25 | $3.23M |
| Q4 2023 | 20 | $1.49M |
| Q3 2023 | 15 | $1.77M |
| Q2 2023 | 14 | $651.4K |
| Q1 2023 | 17 | $1.85M |
| Q4 2022 | 16 | $1.71M |
| Q3 2022 | 16 | $1.68M |
| Q2 2022 | 16 | $1.67M |
| Q1 2022 | 12 | $1.41M |
| Q4 2021 | 13 | $1.85M |
| Q3 2021 | 11 | $2.83M |
| Q2 2021 | 10 | $2.93M |
| Q1 2021 | 9 | $1.78M |
Institutions, Q3 2022
Shares, value and share of portfolio for each institution holding Lexaria Bioscience Corp.; share changes are against Q2 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Invenomic Capital Management LP | 473,103 | $1.16M | 0.10% | +107,891+29.5% | Added |
| Geode Capital Management, LLC | 49,002 | $120.0K | 0.00% | −924−1.9% | Reduced |
| Susquehanna International Group, LLP | 40,119 | $98.0K | 0.00% | +40,119 | New |
| Vanguard Group Inc | 33,164 | $81.0K | 0.00% | −958−2.8% | Reduced |
| Citadel Advisors LLC | 24,874 | $61.0K | 0.00% | −3,014−10.8% | Reduced |
| Dimensional Fund Advisors LP | 15,264 | $37.0K | 0.00% | +15,264 | New |
| Two Sigma Investments, LP | 13,063 | $32.0K | 0.00% | −4,338−24.9% | Reduced |
| Centiva Capital, LP | 13,259 | $32.0K | 0.00% | −900−6.4% | Reduced |
| Renaissance Technologies LLC | 11,900 | $29.0K | 0.00% | +400+3.5% | Added |
| UBS Group AG | 6,398 | $16.0K | 0.00% | +2,227+53.4% | Added |
| Tower Research Capital LLC (TRC) | 3,628 | $9.00K | 0.00% | +3,628 | New |
| Advisor Group Holdings, Inc. | 2,043 | $5.00K | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 1,034 | $2.00K | 0.00% | +2+0.2% | Added |
| Royal Bank of Canada | 394 | $1.00K | 0.00% | 00.0% | Unchanged |
| Aspire Private Capital, LLC | 400 | $1.00K | 0.00% | 00.0% | Unchanged |
| Gables Capital Management Inc. | 13 | $0 | 0.00% | 00.0% | Unchanged |
| Merit Financial Group, LLC | 0 | $0 | 0.00% | −21,267−100.0% | Sold out |
| Virtu Financial LLC | 0 | $0 | 0.00% | −10,975−100.0% | Sold out |
| Citigroup Inc | 0 | $0 | 0.00% | −1,230−100.0% | Sold out |